Duff, Christopher J.

Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM

Nordestgaard, B. G., Langlois, M. R., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H., Borén, J., Bruckert, E., Catapano, A., Cobbaert, C., et al. (2020) · Atherosclerosis

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 246

Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM

Langlois, M. R., Nordestgaard, B. G., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H., Borén, J., Bruckert, E., Catapano, A., Cobbaert, C., et al. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM)

Lipoproteins and Cardiovascular HealthClinical Laboratory Practices and Quality Control

Cited by 211

Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor

Duff, C. J., Scott, M. J., Kirby, I. T., Hutchinson, S. E., Martin, S. L., & Hooper, N. M. (2009) · Biochemical Journal

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 99